ELOVL (ELOngation of Very Long chain fatty acids) Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
Cerulenin directly inhibits fatty acid synthase, thereby potentially decreasing the substrate availability for ELOVL (ELOngation of Very Long chain fatty acids) family. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $72.00 $206.00 $290.00 | 9 | |
C75, a fatty acid synthase inhibitor, indirectly affects ELOVL (ELOngation of Very Long chain fatty acids) family activity by altering fatty acid synthesis. | ||||||
Epalrestat | 82159-09-9 | sc-218319 | 10 mg | $200.00 | 2 | |
An aldose reductase inhibitor that has been shown to affect lipid metabolism, potentially impacting ELOVL activity. | ||||||
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
Orlistat inhibits gastrointestinal lipases and may have indirect effects on ELOVL (ELOngation of Very Long chain fatty acids) family by altering lipid absorption and metabolism. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
As a PPARγ agonist, Rosiglitazone can indirectly affect ELOVL (ELOngation of Very Long chain fatty acids) family by influencing fatty acid storage and metabolism. | ||||||
Nicotinic Acid | 59-67-6 | sc-205768 sc-205768A | 250 g 500 g | $62.00 $124.00 | 1 | |
Nicotinic Acid, a form of vitamin B3, can indirectly influence ELOVL (ELOngation of Very Long chain fatty acids) family by modulating lipid profiles and metabolism. | ||||||